Clinical Trials in Baltimore

Showing 7521-7540 of 23,476 trials

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT02236013

The purpose of this study is to describe the dose limiting toxicities (DLT) and define the maximum tolerated dose (MTD) of ASP2215 when combined with cytarabine/idarubicin or daunorubicin remission induction in a 7+3 schedule. Safety and tolerability of ASP2215 will also be evaluated. This study will also characterize the pharmacokinetics (PK) of ASP2215 when given in combination with cytarabine/idarubicin or cytarabine/daunorubicin remission induction and high-dose cytarabine (HiDAC) consolidation therapy in newly diagnosed acute myeloid leukemia as well as evaluate the effect of ASP2215 on the PK of cytarabine.

Acute Myeloid Leukemia

Astellas Pharma Global Development, Inc.80 participantsStarted Jan 2015

Los Angeles, California, United States • New Haven, Connecticut, United States • Chicago, Illinois, United States +7 more locations

UNKNOWN< 1 mile

Multidisciplinary Approach to Reduce Cardiovascular Health Disparities

NCT06168968

The goal of this observational study is to investigate the potential differences in thrombogenicity between black and white patients admitted with atherothrombotic events including acute coronary syndrome, multi-vessel coronary disease, and ischemic stroke. Participants will engage in laboratory testing and health outcome assessments.

Acute Coronary SyndromeMulti Vessel Coronary Artery DiseaseIschemic Stroke

LifeBridge Health400 participantsStarted Feb 2023

Baltimore, Maryland, United States

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Multidisciplinary Approach to Reduce Cardiovascular Health Disparities

Find Trials by Condition in Baltimore

Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin

Induction Optimization With Stelara for Crohn's Disease

Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso

A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors

Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG

Memory Retrieval and Encoding Investigated by Neural Stimulation

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

A Study of ASP1951 in Subjects With Advanced Solid Tumors

A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)

Preemie Hypothermia for Neonatal Encephalopathy

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients

Vaginal Photobiomodulation for Chronic Pelvic Pain

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

Stratification of Risks of Conversion of Radiologically Isolated Syndromes (RIS) by Identifying Biomarkers in Serum and Cerebrospinal Fluid.